The Goldman Sachs Group Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $150.00

Becton, Dickinson and Company (NYSE:BDX) had its target price decreased by research analysts at The Goldman Sachs Group from $156.00 to $150.00 in a report issued on Wednesday,MarketScreener reports. The firm presently has a “neutral” rating on the medical instruments supplier’s stock. The Goldman Sachs Group’s price target indicates a potential upside of 2.38% from the company’s previous close.

A number of other research analysts have also weighed in on BDX. Stifel Nicolaus dropped their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Jefferies Financial Group reduced their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Piper Sandler decreased their target price on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Argus lowered their price target on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Finally, Barclays increased their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $183.64.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $146.52 on Wednesday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The company has a 50-day moving average price of $152.11 and a 200 day moving average price of $177.44. The company has a market cap of $40.37 billion, a P/E ratio of 36.96, a PEG ratio of 10.46 and a beta of 0.22. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Research analysts predict that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors and hedge funds have recently made changes to their positions in the business. Activest Wealth Management raised its position in Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 97 shares during the last quarter. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. Steph & Co. lifted its stake in Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 65 shares in the last quarter. SHP Wealth Management acquired a new stake in Becton, Dickinson and Company during the 4th quarter valued at $26,000. Finally, Meeder Asset Management Inc. grew its holdings in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 102 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.